Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage

Xu, Kun; Song, Yufeng; Dai, Lianpan; Zhang, Yongli; Lu, Xuancheng; Xie, Yijia; Zhang, Hangjie; Tao, Cheng; Wang, Qihui; Huang, Quan; Bi, Yuhai; Liu, William J.; Liu, Wenjun; Li, Xiangdong; Qin, Chuan; Shi, Yi; Yan, Jinghua; Zhou, Dongming; Gao, George F.

doi:10.1128/jvi.01722-17

Cited by 73 publications

(47 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Screening of immunogenic peptides which are presented by specific MHC I molecules is crucial for the development of vaccines for infection diseases or cancer immunotherapy and for T-cell immune response evaluation (45)(46)(47)(48)(49)(50)(51). Recently, several pre-clinical and clinical studies have shown that vaccines targeting predicted personal tumor neoantigens are feasibility, safety, and immunogenicity (45,50,(52)(53)(54)(55).…”

Section: Discussionmentioning

confidence: 99%

Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides

et al. 2019

Self Cite

View full text Add to dashboard Cite

Human leukocyte antigen (HLA) alleles have a high degree of polymorphism, which determines their peptide-binding motifs and subsequent T-cell receptor recognition. The simplest way to understand the cross-presentation of peptides by different alleles is to classify these alleles into supertypes. A1 and A3 HLA supertypes are widely distributed in humans. However, direct structural and functional evidence for peptide presentation features of key alleles (e.g., HLA-A * 30:01 and -A * 30:03) are lacking. Herein, the molecular basis of peptide presentation of HLA-A * 30:01 and -A * 30:03 was demonstrated by crystal structure determination and thermostability measurements of complexes with T-cell epitopes from influenza virus (NP44), human immunodeficiency virus (RT313), and Mycobacterium tuberculosis (MTB). When binding to the HIV peptide, RT313, the PΩ-Lys anchoring modes of HLA-A * 30:01, and -A * 30:03 were similar to those of HLA-A * 11:01 in the A3 supertype. However, HLA-A * 30:03, but not -A * 30:01, also showed binding with the HLA * 01:01-favored peptide, NP44, but with a specific structural conformation. Thus, different from our previous understanding, HLA-A * 30:01 and -A * 30:03 have specific peptide-binding characteristics that may lead to their distinct supertype-featured binding peptide motifs. Moreover, we also found that residue 77 in the F pocket was one of the key residues for the divergent peptide presentation characteristics of HLA-A * 30:01 and -A * 30:03. Interchanging residue 77 between HLA-A * 30:01 and HLA-A * 30:03 switched their presented peptide profiles. Our results provide important recommendations for screening virus and tumor-specific peptides among the population with prevalent HLA supertypes for vaccine development and immune interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…The 10.8 kb genome of ZIKV encodes a single polyprotein that, upon action of host and viral proteases, forms three structural proteins (C, PrM, and E) and seven nonstructural proteins (NS1-5 NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Ye et al, 2016). Numerous approaches are being employed to develop live attenuated virus (Shan et al, 2017), inactivated whole virus (Sumathy et al, 2017), subunit DNA/RNA vaccines (Pardi et al, 2017;To et al, 2018), virus like particles (Espinosa et al, 2018;Salvo et al, 2018), over virus vectored (Xu et al, 2018), and chimeric ZIKV (Kum et al, 2018;Li et al, 2018) vaccines pertaining to several benefits including economical and long-term immunity. But only a few of them have generated appropriate prophylactic responses in tested in vivo models.…”

Section: Chimeric Zika Virusmentioning

confidence: 99%

Next generation agents (synthetic agents): Emerging threats and challenges in detection, protection, and decontamination

Sharma

Gupta

Ahmad

et al. 2020

Handbook on Biological Warfare Preparedness

View full text Add to dashboard Cite

“…Following humanization, 2A10G6 could be a candidate for immunotherapy. In the second part of his talk, Lianpan presented a chimpanzee adenovirus-based candidate vaccine against ZIKV (Xu et al, 2018). The rationale for using the chimpanzee adenovirus was to take advantage of the low pre-existing immunity against the carrier in the human population (in contrast to human adenovirus).…”

Section: Scientific Sessionsmentioning

confidence: 99%

“…Adenovirus type 7 was engineered to express the ZIKV M and E proteins. A single vaccination elicited potent neutralizing mAbs and achieved sterilizing immunity in mice (Xu et al, 2018). Further assays using a non-human primate model of the disease are planned using this candidate vaccine.…”

Section: Scientific Sessionsmentioning

confidence: 99%

Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018

et al. 2019

Self Cite

View full text Add to dashboard Cite

Singapore, and the USA. Meeting sessions covered aspects of the epidemiology, diagnosis, molecular and structural biology, vaccine development, and antiviral drug discovery for emerging RNA viruses that are current threats in Africa and included flaviviruses (dengue and Zika), alphaviruses (chikungunya), coronaviruses, filoviruses (Ebola), influenza viruses, Crimean Congo hemorrhagic fever virus, Rift Valley fever Virus, Lassa virus, and others. Data were presented on recent flavivirus and/or chikungunyavirus outbreaks in Angola, Burkina Faso, and Mozambique. In addition, these viruses are endemic in many sub-Saharan countries. The TASW series on emerging viruses is unique in Africa and successful in promoting collaborations between researchers in Africa and other parts of the world, as well as among African scientists. This report summarizes the lectures held at the meeting and highlights advances in the field.

show abstract

Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage

Abstract: 38The recent outbreak of Zika virus (ZIKV) has emerged as a global health concern.

Cited by 73 publications

References 57 publications

Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides

Divergent Peptide Presentations of HLA-A*30 Alleles Revealed by Structures With Pathogen Peptides

Next generation agents (synthetic agents): Emerging threats and challenges in detection, protection, and decontamination

Third Tofo Advanced Study Week on Emerging and Re-emerging Viruses, 2018

Contact Info

Product

Resources

About